Promising Findings for Afatinib-Cetuximab Combo in Previously Treated EGFR-Mutant Lung Cancer
July 29th 2014Results of an early-phase study have shown the combination of afatinib (Gilotrif) and cetuximab (Erbitux) has utility in EGFR-mutant lung cancer patients who have developed resistance to gefitinib (Tarceva) and erlotinib (Iressa).
Read More
Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits
July 14th 2014Cardiac events associated with trastuzumab are mostly reversible and outweighed by significant extensions in OS and PFS for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.
Read More
Ofatumumab Misses PFS Endpoint in Bulky CLL
June 30th 2014Ofatumumab (Arzerra) failed to meet its primary endpoint of improvement in progression-free survival (PFS) in a phase III study of the drug versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukemia (CLL),
Read More
Ramucirumab Misses Primary Endpoint in Phase III HCC Trial
June 11th 2014The phase III REACH trial, which examined ramucirumab (Cyramza) for the second-line treatment of patients with hepatocellular carcinoma (HCC), failed to meet its primary endpoint of overall survival (OS), as announced by Eli Lilly and Company, the sponsor of the study and developer of the drug.
Read More
Nab-Paclitaxel Explored as Adjuvant Therapy in Pancreatic Cancer
June 4th 2014While the combination of gemcitabine and nab-paclitaxel (Abraxane) has demonstrated survival benefits for patients with metastatic pancreatic cancer, oncologists are interested in knowing whether the regimen will transfer well into the adjuvant setting
Read More
New Companion Website Provides Inside Look Into "The Story of Cancer"
May 16th 2014WETA, the Washington, DC, public television station, has launched a new website as part of a national outreach for the documentary The Story of Cancer: The Emperor of All Maladies, which will be produced by Ken Burns.
Read More
Long-Term Outcomes Support Sentinel-Node Biopsy for Staging Melanoma
April 22nd 2014A 10-year follow-up study of regional melanoma staging strategies found that patients who underwent sentinel-node biopsies had significantly greater disease-free survival rates (DFSRs) compared with patients monitored through nodal observation.
Read More
I-SPY 2 Trial Graduates Neratinib for HER2-Positive Breast Cancer
April 7th 2014The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer
Read More
Nivolumab Delivers Durable Remissions With Low Toxicity in Advanced Melanoma
March 14th 2014Nivolumab, a PD-1-specific antibody, has been shown to produce long-term remissions with limited toxicity in patients with advanced melanoma, according to results from one of the longest follow ups to examine the drug.
Read More
Ruxolitinib Improves Outcomes for Patients With Polycythemia Vera in Phase III Study
March 7th 2014Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options
Read More
Preventative Ovarian Surgery in BRCA1 Mutation Carriers More Beneficial Before Age 35
February 24th 2014For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.
Read More
Ramucirumab Combination Improves OS and PFS in NSCLC
February 19th 2014The second-line administration of ramucirumab in combination with docetaxel has shown a statistically significant improvement in overall survival and progression-free survival compared with placebo plus docetaxel in patients with non-small cell lung cancer
Read More
Lenvatinib Extends PFS in Differentiated Thyroid Cancer
February 3rd 2014The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.
Read More
ThyroSeq Test Could Reduce Unnecessary Surgeries for Thyroid Cancer
November 20th 2013A new test has been developed to identify the difference between malignant and benign nodules in the thyroid gland, which could potentially reduce the number of unnecessary surgeries, according to an announcement from The University of Pittsburgh Schools of the Health Sciences.
Read More
Treating Renal Cell Carcinoma in 2013: An Interview With Sumanta Kumar Pal, MD
November 19th 2013Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.
Read More
MK-3475 Efficacy Expanded With Longer Follow-Up in Melanoma
November 18th 2013The investigational anti-PD-1 immunotherapy MK-3475 has demonstrated an overall survival rate of 81% at one year in patients with advanced melanoma, according to additional data from a phase Ib clinical trial presented at the 10th International Congress of the Society for Melanoma Research in Philadelphia.
Read More
NY Symposium Tackles Emerging Agents, Pressing Questions in Lung Cancer
November 8th 2013Leaders in thoracic medical oncology from major cancer centers will come together Saturday to discuss advances in the field of lung cancer treatment during the 8th Annual New York Lung Cancer Symposium® in New York City.
Read More
Abiraterone Stalls Pain, Quality of Life Decline in mCRPC
October 11th 2013Abiraterone acetate significantly delayed the progression of pain and quality of life deterioration in chemotherapy-naive men with metastatic castration-resistant prostate cancer when taken in combination with prednisone.
Read More
Dabrafenib and Trametinib Combination Granted Priority Review Designation by FDA
September 16th 2013The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.
Read More